| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10341 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2010-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102150027-B1 |
| titleOfInvention |
Tumor-selective e1a and e1b mutants |
| abstract |
The present invention provides modified Ela regulatory sequences in which one or more Pea3 binding sites or functional portions thereof are deleted. In addition, the present invention provides a modified E1a sequence that selectively expresses a specific isoform. In addition, the present invention provides an E1b-19k clone insertion site. These modified sequences can be used individually or can be used in combination with others that provide oncogenic expression of the protein. |
| priorityDate |
2009-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |